Klinisch orientierter Schwerpunkt
FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz
Fottner, C.; SoWank, S.; Ghiasi, M. et al.
Identification of a Novel MAFA Missense Mutation Causing Familial InsulinomatosisNEUROENDOCRINOLOGY. Bd. 110. 2020 S. 70-70
Kadioglu, Onat; Saeed, Mohamed; Munder, Markus et al.
Identification of Novel Rare ABCC1 Transporter Mutations in Tumor Biopsies of Cancer PatientsCELLS. Bd. 9. H. 2. 2020
Kudo, M.; Ikeda, M.; Zhu, A. X. et al.
IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCCANNALS OF ONCOLOGY. Bd. 31. 2020 S. S1304-S1305
Ikeda, M.; Zhu, A. X.; Qin, S. et al.
IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCCANNALS OF ONCOLOGY. Bd. 31. 2020 S. S698-S699
Heimes, A. S.; Kraemer, H.; Hasenburg, A. et al.
Immunohistochemical analysis of IGCK expression in early breast cancer patients treated with adjuvant chemotherapyGEBURTSHILFE UND FRAUENHEILKUNDE. Bd. 80. H. 10. 2020 S. E99-E99
Heimes, Anne-Sophie; Schmidt, Marcus
Immunotherapy for breast cancerGYNAKOLOGE. Bd. 53. H. 4. 2020 S. 224-228
Nagel, Michael; Labenz, Christian; Woerns, Marcus A. et al.
Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relativesHEALTH AND QUALITY OF LIFE OUTCOMES. Bd. 18. H. 1. 2020
Degenhardt, Tom; Fasching, Peter; Luftner, Diana et al.
Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy - PrecycleCANCER RESEARCH. Bd. 80. H. 4. 2020
Kapp-Schwoerer, Silke; Weber, Daniela; Corbacioglu, Andrea et al.
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trialBLOOD. Bd. 136. H. 26. 2020 S. 3041-3050
Bekes, Inga; Eichler, Martin; Singer, Susanne et al.
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR TrialCLINICAL BREAST CANCER. Bd. 20. H. 6. 2020 S. 439-447